 |
 |
|
|
|
|
|
 |
|
|
Andrew J. Morganti
Email: amorganti@siemion-huckabay.com
Andrew J. Morganti, Siemion Huckabay's Of-counsel to the Complex Litigation, practices in the fields of antitrust and securities litigation. He is a graduate of the Boston University School of Law (LL.M., Banking & Financial Law), and received his law degree from Michigan State University-Detroit College of Law. Mr. Morganti received a B.A., with distinction, from the University of Michigan. While in law school, he was a clerk for the Department of Justice of Canada within the Civil Litigation Department, and at the Federal Reserve Bank of Boston within the Corporate Law Department. Prior to joining Siemion Huckabay, Mr. Morganti was associated with antitrust and shareholders' rights litigation firms based in Chicago and Washington, D.C. Mr. Morganti is a member of the Michigan and District of Columbia Bars, and is admitted to practice in the United States District Court for the Eastern District of Michigan. He is also a member of the Michigan Bar Association, and a member of the American Bar Association's Antitrus Division.
Representing former shareholders of a privately held technology company which was acquired by a publicly traded company in exchange for $24.5 million in restricted stock and cash plus $16 million in performance earn-outs. Shareholders successfully challenged the acquiring company's representations made during the courting process between the two board and successfully defended the acquiring company's $1.7 million counter-claim.
In re Initial Public Offering Securities Litigation, 241 F.Supp.2d 281 (S.D.N.Y. 2003) (challenging the method which investment banks allocated "new economy" initial public offerings and resulting stock bubble between 1998 and 2000).
In re Northwest Airlines Antitrust Litigation, 208 F.R.D. 174 (E.D. Mich. 2002) (successfully challenged the legality of the airline industry's prohibition against hidden city ticketing).
In re Cardizem CD Antitrust Litigation, 200 F.R.D. 326 (E.D. Mich. 2001) (successfully challenged a patent infringement settlement between a branded and a generic pharmaceutical company, which resulted in the branded paying the generic not to compete).
|
|
|
|
|
|
